AI Article Synopsis
- Treatment of hematologic disorders like sickle cell disease and aplastic anemia is challenging in low-income countries due to resource limitations.
- Pediatric hematologists from 15 LIC reported effective use of low-dose hydroxyurea for sickle cell disease, which helped minimize pain crises.
- Patients with severe aplastic anemia struggled because of the high cost and limited availability of essential treatments, highlighting the importance of partnerships with higher-income centers for better care.
Article Abstract
Treatment of hematologic disorders in low-income countries (LIC) is difficult. This report summarizes treatment of sickle cell disease and aplastic anemia by pediatric hematologists from 15 LIC who participate in the Monza International School of Pediatric Hematology/Oncology (MISPHO). Patients with severe sickle cell disease were treated with low dose hydroxyurea, which safely reduced vaso-occlusive crises. Patients with severe aplastic anemia fared poorly due to lack of availability and high cost of anti-thymocyte globulin and cyclosporine and lack of access to stem cell transplantation. Appropriate therapy was most likely to occur in MISPHO centers with an active twinning program with a center in a high-income country.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.20988 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!